Early trial shows investigational orexin-2 agonist ALKS 7290 improves adult ADHD symptoms in 14 days, with tolerable safety, paving way for phase 2.
|Slideshows|March 24, 2017
6 Challenges in Assessing ADHD in Adult Patients
The clinical presentation and functional impacts of ADHD in adults vary greatly from their child and adolescent counterparts.
Advertisement
View a PDF of this article.
Advertisement
Related to this article
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
New US adult ADHD guidance nears publication, promising clearer diagnosis, comorbidity screening, and clinician training to curb misdiagnosis.
FDA clears Simtriyo, first NDSRI stimulant for ADHD ages 6 and older, as millions return to school—see what this means for treatment.
How postmodern ideas shape DSM and the biopsychosocial model—why psychiatry needs method-based, truth-seeking care beyond consensus and eclecticism.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
2
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
3
The Adolescent Brain and Schizophrenia: What Research Reveals About Pruning, Dopamine, and Myelin
4
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
5